Short Interest Filing: What’s Next for Diplomat Pharmacy Incorporated (NYSE:DPLO) After Having More Shares Shorted?

December 1, 2016 - By Nellie Frank   ·   0 Comments

Short Interest Filing: What's Next for Diplomat Pharmacy Incorporated (NYSE:DPLO) After Having More Shares Shorted?

The stock of Diplomat Pharmacy Incorporated (NYSE:DPLO) registered an increase of 7.29% in short interest. DPLO’s total short interest was 10.78 million shares in December as published by FINRA. Its up 7.29% from 10.05 million shares, reported previously. With 1.18M shares average volume, it will take short sellers 9 days to cover their DPLO’s short positions. The short interest to Diplomat Pharmacy Incorporated’s float is 24.76%. About 261,642 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 54.93% since April 28, 2016 and is downtrending. It has underperformed by 60.86% the S&P500.

Diplomat Pharmacy, Inc. operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The company has a market cap of $913.82 million. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. It has a 29 P/E ratio. The Firm operates through specialty pharmacy services segment.

Insitutional Activity: The institutional sentiment increased to 1.82 in 2016 Q2. Its up 0.39, from 1.43 in 2016Q1. The ratio is positive, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Bnp Paribas Arbitrage Sa has 0% invested in the company for 11,702 shares. The New York-based Lazard Asset Mngmt Lc has invested 0.01% in Diplomat Pharmacy Inc (NYSE:DPLO). Adage Grp Incorporated Ltd Liability Corp accumulated 700,000 shares or 0.07% of the stock. The Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Parkside Natl Bank & Tru holds 0% or 71 shares in its portfolio. Nuveen Asset Mngmt Ltd Liability Corporation holds 0.01% or 34,815 shares in its portfolio. Granite Ptnrs Ltd Liability Corp last reported 0.95% of its portfolio in the stock. Moreover, Blackrock Advisors Ltd has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 100,437 shares. Gilder Gagnon Howe And Com Limited Com holds 77,388 shares or 0.05% of its portfolio. Weatherbie Capital Llc last reported 1.29% of its portfolio in the stock. New York State Teachers Retirement System has invested 0% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). The Maryland-based Price T Rowe Md has invested 0.04% in Diplomat Pharmacy Inc (NYSE:DPLO). Kayne Anderson Rudnick Investment Limited Liability has 0.02% invested in the company for 33,024 shares. Schwab Charles Invest Mngmt holds 128,231 shares or 0.01% of its portfolio. Mirae Asset Global Investments Com Ltd, a Korea-based fund reported 28,697 shares.

Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 2 sales for $1.04 million net activity. On Monday, August 1 Kaddis Atheer A sold $440,794 worth of the stock or 12,325 shares.

Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage

Out of 10 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 1 “Sell”, while 7 “Hold”. This means 20% are positive. Diplomat Pharmacy has been the topic of 17 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by UBS given on Wednesday, October 21. Mizuho maintained Diplomat Pharmacy Inc (NYSE:DPLO) rating on Wednesday, October 21. Mizuho has “Buy” rating and $44 price target. Mizuho maintained the shares of DPLO in a report on Wednesday, May 11 with “Neutral” rating. The firm has “Outperform” rating given on Tuesday, August 4 by Leerink Swann. Mizuho maintained Diplomat Pharmacy Inc (NYSE:DPLO) on Thursday, November 3 with “Neutral” rating. The firm earned “Neutral” rating on Tuesday, June 7 by Bank of America. The firm earned “Overweight” rating on Wednesday, January 6 by Barclays Capital. Morgan Stanley downgraded Diplomat Pharmacy Inc (NYSE:DPLO) rating on Friday, October 2. Morgan Stanley has “Equal-Weight” rating and $31 price target. Bank of America upgraded the shares of DPLO in a report on Wednesday, October 14 to “Neutral” rating. Cowen & Co maintained the shares of DPLO in a report on Thursday, November 3 with “Market Perform” rating.

DPLO Company Profile

Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

More important recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016, also Fool.com published article titled: “Can Diplomat Pharmacy Turn Things Around in 2017?”, Prnewswire.com published: “Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Diplomat Pharmacy …” on November 16, 2016. More interesting news about Diplomat Pharmacy Inc (NYSE:DPLO) was released by: Businesswire.com and their article: “Robbins Arroyo LLP: Diplomat Pharmacy, Inc. (DPLO) Misled Shareholders …” with publication date: November 15, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Nellie Frank


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>